SOURCE: BioProgress PLC

November 03, 2005 03:47 ET

BioProgress PLC - Change of Adviser

Cambridgeshire -- (MARKET WIRE) -- November 3, 2005 --BioProgress plc ("BioProgress" or the "Company")

Appointment of new advisor

The Board of BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the provider of innovative delivery mechanisms for the pharmaceutical oral dosage markets, is pleased to announce the appointment of Robert W. Baird Limited as sole nominated adviser and broker to the Company with immediate effect.

3 November 2005


For further details please contact:

BioProgress plc                                         01354 655674
Richard Trevillion, Chief Executive Officer             www.bioprogress.com
Dan Farrow, Finance Director

Robert W. Baird                                         020 7488 1212
Shaun Dobson/ Xavier de Mol

College Hill                                            020 7457 2020
Corinna Dorward/ Adrian Duffield

Forward-Looking Information

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company's filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.


                      This information is provided by RNS
            The company news service from the London Stock Exchange